Fig. 4.

Exposure-adjusted incidence rate of TEAEs at 1-year intervals to year 3. The data points on the graph are the IR (95% CI)/100 PY at successive 1-year interval to year 3 for all ixekizumab-treated dataset (SPIRIT-P1, SPIRIT-P2, SPIRIT-P3) for a serious infections, b MACE (CEC-adjudicated), c NMSC, d other malignancies (excluding NMSC), e depression, and f IBD related. The CIs for the IRs are from likelihood ratio test of treatment effect from the Poisson regression model. The AEs were coded using MedDRA Version 19.1. ^*95% CI was not evaluated for IBD. AE: adverse event; CEC: Clinical Events Committee; CI: confidence interval; IBD: inflammatory bowel disease; IR: incidence rate; IXE: ixekizumab; MACE: major adverse cardiovascular events; MedDRA: Medical Dictionary for Regulatory Activities; Ns: number of patients entered in each time interval; n: number in group; PBO: placebo; PY: patient-years; Q2W: every 2 weeks; Q4W: every 4 weeks; TEAEs: treatment-emergent adverse events